BACKGROUNDThe Japanese National Immunization Program currently includes the pediatric 13 valent pneumococcal conjugate vaccine (PCV13) to prevent pneumococcal infections. We aimed to evaluate the cost-effectiveness of 20-valent PCV (PCV20) as a pediatric vaccine versus PCV13.METHODSA decision-analytic Markov model was used to estimate expected costs, quality-adjusted life-years (QALYs), and prevented cases and deaths caused by invasive pneumococcal disease, pneumonia, and acute otitis media over a ten-year time horizon from the societal and healthcare payer perspectives.RESULTSPCV20 was dominant, i.e. less costly and more effective, over PCV13 (gained 294,599 QALYs and reduced Japanese yen [JPY] 352.6 billion [2.6 billion United States dollars, USD] from the societal perspective and JPY 178.9 billion [USD 1.4 billion] from the payer perspective). Sensitivity and scenario analyses validated the robustness of the base scenario results. When comparing PCV20 with PCV13, the threshold analysis revealed an incremental cost-effectiveness ratio that was within the threshold value (JPY 5 million/QALY) at a maximum acquisition cost of JPY 74,033 [USD 563] (societal perspective) and JPY 67,758 [USD 515] (payer perspective).CONCLUSIONSAs a pediatric vaccine, PCV20 was dominant over PCV13 regardless of the study perspective.

2024-10-01·Vaccine

Persistence of immunity in children aged 2 months and 7 months – 5 years old after primary immunization with 13-valent pneumococcal conjugate vaccine

Article

作者: Guan, Yanxin ; Liu, Jiankai ; Yin, Shanshan ; Ti, Jing ; Liang, Qi ; Li, Guifan ; Liu, Gaoran ; Chang, Xianyun ; Ren, Tao ; Zhang, Hao

BACKGROUNDPneumococcus is a common cause of pneumonia, meningitis, and other serious infections in children. The previous study has proved that the 13-valent pneumococcal conjugate vaccine (PCV13) has sufficient immunogenicity in children. The data on long-term persistence of immunity will help the follow-up development work of pneumococcal vaccines.METHODSChildren who received the full vaccination course of the tested PCV13 in the previous clinical trial were enrolled again, and these who received other pneumococcal vaccines, or were infected with one or more serotypes of S. pneumoniae corresponding to PCV13 before enrollment were excluded. Participants were divided into four groups by age which is same as that of previous trial. The study lasted for 5 years, during which we measured pneumococcal antibodies of 13 serotypes included in PCV13 at particular points in time. Geometric mean concentrations (GMCs) and seropositive rates (the rate of IgG concentration ≥0.35 μg/mL) of antibodies against 13 serotypes were calculated.RESULTSFor the participants aged 2 months, five years after primary vaccination, except for serotypes 3 and 4, seropositive rates were 100%. GMCs of IgG antibodies against 13 serotypes ranged from 0.733 to 15.160 μg/mL. All of the participants aged 7-11 months had the serotype-specific IgG concentration ≥0.35 μg/mL four years after primary vaccination with the exception of serotypes 3, 4, 6 A and 9 V. IgG GMCs were 0.753-11.031 μg/mL. All participants aged 12-23 months and 2-5 years old had the serotype-specific IgG concentration ≥0.35 μg/mL three or two years after primary vaccination respectively, except for serotype 3. IgG GMCs ranged from 0.815 to 13.111 μg/mL, and 0.684 to 12.282 μg/mL respectively.CONCLUSIONPCV13 was applied to the population aged 2 months and 7 months - 5 years old with a good immune persistence, providing more extensive evidence of long-term efficacy for that vaccine.TRIAL REGISTRATIONThe trial was registered with ClinicalTrials.gov, number NCT06210737.

2024-09-01·Vaccine

Cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the pediatric population in South Korea

Article

作者: Byun, Bo-Kyung ; June Choe, Young ; Park, Sun-Kyeong ; Suk, In-Ae ; Lee, Ju-Yeon ; Kang, Dong-Won ; Kim, Hak-Yeon ; Kim, Young-Soo

OBJECTIVESTo evaluate the cost-effectiveness of the 20-valent pneumococcal conjugate vaccine (PCV20) compared to 13-valent pneumococcal conjugate vaccine (PCV13) for the pediatric population in Korea, where the four-dose vaccine coverage rate is over 97%.METHODSWe constructed a Markov model to calculate the cost and quality-adjusted life-years (QALYs) over 10 years. The health states were susceptible states; disease states, which included invasive pneumococcal diseases such as meningitis, bacteremia, pneumonia, and acute otitis media; and death attributable to pneumococcal disease. The annual incidence and mortality due to pneumococcal diseases were estimated based on the serotypes covered by PCV13 and PCV20, vaccine coverage rate, vaccine effectiveness, and population size. Vaccine, administration, and disease costs were included in the model.RESULTSIn the total population (n = 51,431,305), PCV20 prevented more pneumococcal diseases and deaths, resulting in a gain of 74,855 QALY over PCV13. Meanwhile, the PCV20 group spent $275,136,631 less than the PCV13 group. As PCV20 gained more QALYs but spent less on total medical costs than PCV13, PCV20 was dominant over PCV13.CONCLUSIONSIn the Korean population, PCV20 is a cost-effective and dominant option over PCV13. Our findings provide evidence for decision-making regarding the introduction of PCV20 in countries with high vaccine coverage.

100 项与 13价肺炎球菌结合疫苗 (苏州超微) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肺炎球菌感染	临床1期	中国	苏州微超生物科技有限公司	2022-03-23

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ACR2017	N/A	类风湿关节炎	24	PCV1313-Valent Pneumococcal Conjugate VaccinePPV23umococcal Conjugate Vaccine (PCV13 + PPV23 prime-boost revaccination)	積鬱製襯願餘鏇獵遞範(鏇廠憲淵淵膚觸艱觸艱) = 壓願艱選獵膚積衊願簾顧構壓艱窪淵醖齋觸衊 (壓艱範餘膚選製築餘衊 )	不佳	2017-11-07
				13-Valent Pneumococcal Conjugate VaccinePPV23lent Pneumococcal Conjugate Vaccine (PPV23 alone)	積鬱製襯願餘鏇獵遞範(鏇廠憲淵淵膚觸艱觸艱) = 鹹鑰繭鹽蓋齋構願簾簾顧構壓艱窪淵醖齋觸衊 (壓艱範餘膚選製築餘衊 )